Results

eNauka >  Rezultati >  Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
Naziv: Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
Autori : Peters, Solange; ...; Andric, Zoran G  ; ...; (broj, koautora 26)
Godina: 2022
Publikacija: NATURE MEDICINE
ISSN: 1078-8956 Nature Medicine Pretraži identifikator
Tip rezultata: Naučni članak
Kolacija: vol. 28 br. 9 str. 1831-1839
DOI: 10.1038/s41591-022-01933-w
WoS-ID: 000842907100002
Scopus-ID: 2-s2.0-85136993595
PMID: 35995953
PMCID: PMC9499854
URI: https://enauka.gov.rs/handle/123456789/810648
Projekat: F. Hoffmann-La Roche, Ltd.
Izvor metapodataka: (Preuzeto iz Nasi u WoS)
M-kategorija: 
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+

94
SCOPUSTM
65
PubMed CentralTM
4
OpenCitations
92
WEB OF SCIENCETM
Altmetric
Dimensions
Unpaywall

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.